Once-daily gentamicin in infants and children: A prospective cohort study evaluating safety and the role of therapeutic drug monitoring in minimizing toxicity

Pediatric Infectious Disease Journal

Volumn 30, Issue 10, 2011, Pages 827-832

  Best, Emma J ^a,b   Gazarian, Madlen ^a   Cohn, Richard ^a,b   Wilkinson, Monica ^b,c   Palasanthiran, Pamela ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

Author keywords

adverse drug reaction reporting systems; aminoglycosides; drug monitoring; drug toxicity; gentamicins; hearing loss; MeSH; sensorineural (etiology)

Indexed keywords

GENTAMICIN;

ABDOMINAL DISEASE; ARTICLE; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; DRUG MONITORING; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HEARING LOSS; HUMAN; INFANT; INFANT DISEASE; INTRA ABDOMINAL SEPSIS; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NOMOGRAM; OTOTOXICITY; PATIENT ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; SEPSIS; URINARY TRACT INFECTION;

EID: 80052955039     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31821e405d     Document Type: Article

References (31)

1. Barza M, Ioannidis JP, Cappelleri JC, et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ. 1996;312:338-345. (Pubitemid 26049400)
2. Barclay ML, Begg EJ, Hickling KG. What is the evidence for once-daily aminoglycoside therapy? Clin Pharmacokinet. 1994;27:32-48. (Pubitemid 24211095)
3. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997;24:796-809. (Pubitemid 27193857)
4. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother. 1996;37:645-663. (Pubitemid 26134115)
5. Chuck SK, Raber SR, Rodvold KA, et al. National survey of extended-interval aminoglycoside dosing. Clin Infect Dis. 2000;30:433-439. (Pubitemid 30205284)
6. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, et al. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics. 2004; 114:e111-e118.
7. Best EJ, Palasanthiran P, Gazarian M. Extended-interval aminoglycosides in children: more guidance is needed. Pediatrics. 2005;115:827.
8. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol. 1995;39:605-609.
9. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39:650-655.
10. Tomlinson RJ, Ronghe M, Goodbourne C, et al. Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia. Arch Dis Child. 1999; 80:125-131. (Pubitemid 29119723)
11. McCormack JP, Jewesson PJ. A critical reevaluation of the "therapeutic range" of aminoglycosides. Clin Infect Dis. 1992;14:320-339.
12. Best EJ. Once daily gentamicin in infants and children; an evaluation of safety and the role of therapeutic drug monitoring in minimising toxicity [Masters of Medicine thesis]. University of New South Wales; 2007. Available at: http://adt.caul.edu.au/[Australian Digital Theses Program Database]. Accessed February, 2011.
13. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children and adolescents. Pediatr Clin North Am. 1987;34:571-590. (Pubitemid 17080631)
14. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245. (Pubitemid 12149145)
15. Tapaneya-Olarn C, Tapaneya-Olarn W, Pitayamornwong V, et al. Single daily dose of gentamicin in the treatment of pediatric urinary tract infection. JMed Assoc Thai. 1999;82(S1):S93-S97.
16. Uijtendaal EV, Rademaker CM, Schobben AF, et al. Once-daily versus multiple-daily gentamicin in infants and children. Ther Drug Monit. 2001; 23:506-513. (Pubitemid 32912271)
17. Carapetis JR, Jaquiery AL, Buttery JP, et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatr Infect Dis J. 2001;20:240-246. (Pubitemid 32240260)
18. Vigano A, Principi N, Brivio L, et al. Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of Gram-negative pyelonephritis in children. Antimicrob Agents Chemother. 1992;36:1499-1503.
19. Bertino JS Jr, Rotschafer JC. Single daily dose of aminoglycosides-a concept whose time has not yet come. Clin Infect Dis. 1997;24:820-823. (Pubitemid 27193860)
20. Chong CY, Tan AS, Ng W, et al. Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatr. 2003;92:291-296. (Pubitemid 36408082)
21. Luft FC. Clinical significance of renal changes engendered by aminogly-cosides in man. J Antimicrob Chemother. 1984;13:23-30.
22. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental Pharmacology-drug disposition, action and therapy in infants and children. N Engl J Med. 2003;349:1157-1167. (Pubitemid 37122329)
23. El Bakri F, Pallett A, Smith AG, et al. Ototoxicity induced by once-daily gentamicin. Lancet. 1998;351:1407-1408. (Pubitemid 28210007)
24. Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004;38:1538-1544. (Pubitemid 38738547)
25. Bitner-Glindzicz M, Pembrey M, Duncan A, et al. Prevalence of mitochon-drial 1555A-G mutation in European children. N Engl J Med. 2009;360: 640-642.
26. Stavroulaki P, Apostolopoulos N, Segas J, et al. Evoked otoacoustic emissions-an approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol. 2001;59:47-57. (Pubitemid 32453343)
27. Riggs LC, Brummett RE, Guitjens SK, et al. Ototoxicity resulting from combined administration of cisplatin and gentamicin. Laryngoscope. 1996; 106:401-406. (Pubitemid 26120121)
28. Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotox-icity and ototoxicity. Antimicrob Agents Chemother. 1999;43:1549-1555. (Pubitemid 29331226)
29. Schentag JJ, Jusko WJ, Plaut ME, et al. Tissue persistence of gentamicin in man. JAMA. 1977;238:327-329. (Pubitemid 8156720)
30. Kirkpatrick CM, Duffull SB, Begg EJ, et al. The use of a change in gentamicin clearance as an early predictor of gentamicin-induced nephro-toxicity. Ther Drug Monit. 2003;25:623-630. (Pubitemid 37238897)
31. Guidelines for Preparing Core Clinical Safety Information on Drugs-Report of CIOMS Working Group III, Chapter 5, Good Safety Information Practices. Geneva, Switzerland: WHO, 1995.